Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stock Holdings Boosted by Xponance Inc.

Xponance Inc. boosted its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 6.8% during the 4th quarter, HoldingsChannel reports. The firm owned 18,763 shares of the biopharmaceutical company’s stock after buying an additional 1,189 shares during the quarter. Xponance Inc.’s holdings in Catalyst Pharmaceuticals were worth $392,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of CPRX. Steward Partners Investment Advisory LLC bought a new stake in shares of Catalyst Pharmaceuticals during the fourth quarter valued at approximately $27,000. Farther Finance Advisors LLC raised its stake in Catalyst Pharmaceuticals by 125.1% during the 4th quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock valued at $56,000 after acquiring an additional 1,495 shares in the last quarter. Larson Financial Group LLC boosted its position in Catalyst Pharmaceuticals by 27,218.2% during the 3rd quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock worth $60,000 after acquiring an additional 2,994 shares during the period. Wilmington Savings Fund Society FSB bought a new position in shares of Catalyst Pharmaceuticals in the fourth quarter worth $65,000. Finally, KBC Group NV increased its holdings in shares of Catalyst Pharmaceuticals by 48.8% during the fourth quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company’s stock valued at $98,000 after purchasing an additional 1,542 shares during the period. 79.22% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. Baird R W raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Monday, February 3rd. Bank of America reaffirmed a “buy” rating and issued a $30.00 price target on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. HC Wainwright reissued a “buy” rating and set a $35.00 target price on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. StockNews.com upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 28th. Finally, Robert W. Baird lifted their price target on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an “outperform” rating in a research report on Monday, March 3rd. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $32.29.

Insider Activity

In other news, insider Gary Ingenito sold 44,904 shares of the business’s stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total transaction of $991,929.36. Following the sale, the insider now owns 68,873 shares in the company, valued at $1,521,404.57. The trade was a 39.47 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Brian Elsbernd sold 62,975 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the completion of the transaction, the insider now directly owns 188,564 shares of the company’s stock, valued at $4,333,200.72. This represents a 25.04 % decrease in their position. The disclosure for this sale can be found here. 11.00% of the stock is currently owned by company insiders.

Catalyst Pharmaceuticals Stock Performance

Shares of NASDAQ:CPRX opened at $25.15 on Thursday. The company has a market capitalization of $3.05 billion, a PE ratio of 21.31, a price-to-earnings-growth ratio of 3.31 and a beta of 0.84. The stock has a fifty day moving average of $22.57 and a 200-day moving average of $21.74. Catalyst Pharmaceuticals, Inc. has a one year low of $14.47 and a one year high of $26.16.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.